|Bid||125.10 x 900|
|Ask||158.00 x 900|
|Day's Range||128.52 - 131.55|
|52 Week Range||116.50 - 155.33|
|Beta (3Y Monthly)||0.83|
|PE Ratio (TTM)||22.24|
|Earnings Date||May 1, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||154.69|
"Market conditions are changing. The continued rise in interest rates suggests we are in the early stages of a bond bear market, which could intensify as central banks withdraw liquidity. The receding tide of liquidity will start to reveal more rocks beyond what has been exposed in emerging markets so far, and the value of […]
The worst result, after buying shares in a company (assuming no leverage), would be if you lose all the money you put in. But on a lighter note, a good company can see its share price rise well over 100%. For instance, t...
ICON PLC NASDAQ/NGS:ICLRView full report here! Summary * ETFs holding this stock are seeing positive inflows but are weakening * Bearish sentiment is low * Economic output in this company's sector is expanding Bearish sentimentShort interest | PositiveShort interest is extremely low for ICLR with fewer than 1% of shares on loan. This could indicate that investors who seek to profit from falling equity prices are not currently targeting ICLR. Money flowETF/Index ownership | NegativeETF activity is negative and may be weakening. The net inflows of $187 million over the last one-month into ETFs that hold ICLR are among the lowest of the last year and appear to be slowing. Economic sentimentPMI by IHS Markit | PositiveAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is strong relative to the trend shown over the past year, and is accelerating. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to firstname.lastname@example.org.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
ICON plc, (ICLR) a global provider of drug development and commercialisation services to the pharmaceutical, biotechnology and medical device industries, has won awards across several categories in the annual CRO Leadership Awards. ICON received 2019 CRO Leadership Awards in five categories, each further divided into three groups – Big Pharma, Small Pharma, and Overall.
NEW YORK, Feb. 27, 2019 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
Want to participate in a short research study? Help shape the future of investing tools and receive a $20 prize! ICON Public Limited Company's (NASDAQ:ICLR) latest earnings update in DecemberRead More...
PORTLAND, Ore. and CAMBRIDGE, Mass., Feb. 21, 2019 -- MolecularMD Corporation, a molecular diagnostic specialty laboratory that enables the development and commercialisation.
Icon PLC (ICLR) delivered earnings and revenue surprises of 1.25% and 0.47%, respectively, for the quarter ended December 2018. Do the numbers hold clues to what lies ahead for the stock?
On a per-share basis, the Dublin-based company said it had net income of $1.62. The results exceeded Wall Street expectations. The average estimate of eight analysts surveyed by Zacks Investment Research ...
Icon PLC (ICLR) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
ICON plc, (ICLR) a global provider of drug development solutions and services to the pharmaceutical, biotechnology and medical device industries, today announced the release of a new drug safety reporting solution based on an innovative cloud-based system, featuring automated and configurable business rules. The solution ensures compliance in an increasingly complex regulatory environment and enables the sponsor to gain visibility into the safety profile of an investigational product throughout its lifecycle. Using regulatory intelligence from 80 countries, the system is configured with date-stamped decision rules.
In September 2018, ICON Public Limited Company (NASDAQ:ICLR) released its earnings update. Generally, analyst forecasts appear to be conservative, with earnings growth rate expected to be 17% next year, which Read More...
ICON plc (ICLR), a global provider of drug development solutions and services to the pharmaceutical, biotechnology and medical device industries, today announced its financial guidance for the year ended December 31, 2019. For the full year 2019 revenue is expected to be in the range of $2,735 - $2,835 million, representing growth of 5.2 – 9.0% and earnings per share is expected to be in the range of $6.69 - $6.89, representing growth of 10.6 – 13.9%.
As an investor, I look for investments which does not compromise one fundamental factor for another. By this I mean, I look at stocks holistically, from their financial health to Read More...
While the market driven by short-term sentiment influenced by uncertainty regarding the future of the interest rate environment in the US, declining oil prices and the trade war with China, many smart money investors are keeping their optimism regarding the current bull run, while still hedging many of their long positions. However, as we know, […]
Small and large cap stocks are widely popular for a variety of reasons, however, mid-cap companies such as ICON Public Limited Company (NASDAQ:ICLR), with a market cap of US$7.9b, often Read More...